



Washington, DC | September 5-9

Presentation Abstract

Add to Itinerary

Print

Session: 085-Ceftaroline and New Beta-Lactam/Beta-Lactamase Inhibitor Combinations: The Real Efficacy

Sunday, Sep 07, 2014, 11:00 AM - 1:00 PM

Presentation Title: C-760 - *In Vitro* Activity of Ceftaroline against Contemporary *Staphylococcus aureus* Isolates (2013) from Latin American Countries: AWARE Surveillance Program

Location: Exhibit Hall B

Presentation Number: C-760

Pres. Time: Sunday, Sep 07, 2014, 11:00 AM - 1:00 PM

Category: C

Keywords: Ceftaroline; *Staphylococcus aureus*; Latin America

Author(s): **D. Hoban**<sup>1</sup>, M. Hackel<sup>1</sup>, R. Badal<sup>1</sup>, E. Reiszner<sup>2</sup>, J. Ambler<sup>2</sup>;  
<sup>1</sup>Intl. Hlth. Management Associates, Inc., Schaumburg, IL,  
<sup>2</sup>AstraZeneca Pharmaceuticals LP, Waltham, MA

Financial Disclosures: **D. Hoban,**  
**AstraZeneca Role(s):** Independent Contractor.  
**M. Hackel,**

**AstraZeneca Role(s):** Independent Contractor.

**R. Badal,**

**AstraZeneca Role(s):** Independent Contractor.

**E. Reiszner,**

**AstraZeneca Role(s):** Employee.

**J. Ambler,**

**AstraZeneca Role(s):** Employee.

**Abstract:** **Background:** Ceftaroline (CPT), the active metabolite of ceftaroline fosamil is the first cephalosporin with enhanced anti-staphylococcal activity (including methicillin-resistant *S. aureus* [MRSA]) indicated for the treatment of adults with complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP). This report from AWARE, a global CPT surveillance program, summarizes the *in vitro* activity of CPT against *S. aureus* isolates collected in Latin America (LA). **Methods:** Susceptibility testing of 1,182 *S. aureus* isolates (488 methicillin-susceptible *S. aureus*, 694 MRSA) collected in 2013 from 22 hospitals, in 6 LA countries (Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela). Isolates were sourced from specimens from patients with SSTI (abscess, burn, carbuncle, cellulitis/erysipelas, decubitus, furuncle, impetiginous lesions, skin ulcer, wound) and lower respiratory tract infections (bronchial washing, bronchial alveolar lavage, endotracheal aspirate, sputum). Testing was performed by broth microdilution and MIC results were interpreted according to CLSI performance standards. **Results:** Of the 1,182 *S. aureus* tested 88.4% were CPT susceptible. All MSSA isolates were CPT susceptible (MIC range 0.06-0.5 mg/L, MIC<sub>90</sub> 0.25 mg/L). CPT activity against MRSA isolates is summarized in the table.

Country (n)	N	Ceftaroline (mg/L)						MIC <sub>50/90</sub>	%S
		0.25	0.5	1	2	4			
Argentina (3)	156	4	135	7	10	-	0.5/1	93.6	
Brazil (5)	61	4	22	19	16	-	1/2	73.8	
Chile (3)	125	3	28	8	86	-	2/2	31.2	
Colombia (3)	44	3	38	3	-	-	0.5/0.5	100	

Mexico (5)	144	2	34	105	3	-	1/1	97.9
Venezuela (3)	164	5	133	4	21	1	0.5/2	86.6
LA Region (22)	694	21	390	146	136	1	0.5/2	80.3

n = number of sites; N = number of MRSA isolates; %S= percent

susceptible **Conclusions:** All MSSA isolates were susceptible *in vitro* to CPT. Marked diversity in susceptibility across LA countries was observed *in vitro* with MRSA (%S ranged from 31.2% in Chile to 100% in Colombia). Across the LA region 80.3% of MRSA were reported as susceptible, 19.6% as intermediate and 0.1% (1 isolate) as resistant with an MIC of 4 mg/L.

---

**Note:** When adding items to your Itinerary, please click "Add Checked Selections to My Itinerary" on EACH page of your search results.

### ICAAC 2014 Meeting Information

#### **Technical Support**

Phone: 217-398-1792

Email: Help Desk

Share | .....

American Society for Microbiology

1752 N Street NW

Washington, DC 20036

Email: icaacpc@asmusa.org

Phone: (202) 737-3600

#### **TECHNICAL SUPPORT:**

**217-398-1792 (Monday through Friday 9:00 am-5:00 pm Central Standard Time)**

or OASIS Helpdesk

---

[Leave OASIS Feedback](#)

---

Powered by



**The Online  
Abstract  
Submission  
and Invitation  
System  
© 1996 - 2014  
Coe-Truman  
Technologies,  
Inc. All rights  
reserved.**

Services by



Coe-Truman Technologies, Inc.